Some of the leading voices in biopharma have had a difficult time over the last 4 years watching Donald Trump march through American history with an often fractious view of the drug industry. Biopharma leaders and organizations have condemned the administration’s immigration policies and vehemently objected to Trump’s drug pricing proposals. But they also enjoyed the warm embrace of Trump’s Operation Warp Speed in a sprint to develop new vaccines and drugs for Covid-19, with heavy government subsidies, even if the president also accused Pfizer of dragging its feet on their application for an OK to get clear of voting day.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

After a breakup, it’s OK to take some time for yourself — revisit that hobby you left behind, start journaling, maybe drop a few pounds. Or, if you’re an iconic pharmaceutical brand, launch that ambitious redesign you’ve planned for years; it’s a new year, after all, and you deserve it.

With the spinoff of its Upjohn unit and branded Viagra in the books, Pfizer is ringing in the new year with a brand new logo — the company’s first redesign in decades — as it looks at a slimmed-down future without the generics yoke around its neck.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

It looks like AstraZeneca may have a bonus waiting once it’s done acquiring Alexion.

Yesterday, Rhythm Pharmaceuticals put out word that the biotech sold their newly won priority review voucher for $100 million — but without identifying the buyer. And then, after the market close, we found out in an SEC filing that the mystery buyer was Alexion.

Alexion has been scooping up new approvals for its Soliris successor, Ultomiris, with an emergency Phase III underway for Covid-19. But there’s not a lot of new drugs in the late-stage pipeline lining up for a run at a quick OK.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

In a pitched battle against Merck’s Keytruda, Bristol Myers Squibb’s immunotherapy headliner Opdivo landed a major salvo with a groundbreaking FDA approval for certain lung cancer patients back in 2018. Since that nod, however, Opdivo has turned out clinical duds in that market, and now Bristol is cutting its losses.

Bristol has agreed to give up Opdivo’s third-line-or-later FDA approval for small-cell lung cancer after confirmatory trials for an accelerated nod in that indication back in 2018 failed to show benefit in extending patients’ lives, the drugmaker said Tuesday.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

UK regulators are reportedly set to approve AstraZeneca’s Covid-19 vaccine this week, but don’t expect it to be available across the channel anytime soon.

A top EMA official told a Brussels newspaper this week that European authorities have yet to receive all the data necessary for approval from the British Pharma, leaving them unable to render a verdict. Asked why it would be OK’d on the isle, the official, EMA deputy executive director Noël Wathion, said he could only speculate.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

Bristol Myers Squibb has seen setback after setback for its chances to bring immuno-oncology blockbuster Opdivo into newly diagnosed brain cancer patients — a sort of holy grail for the field. Despite holding a slim hope Opdivo would turn around its chances, Bristol is ready to call it quits for now.

Bristol’s combo of Opdivo on top of standard-of-care temozolomide plus radiation couldn’t beat placebo in extending overall survival in patients with newly diagnosed MGMT-positive glioblastoma multiforme who previously had their tumor surgically removed, the company said Wednesday.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN